Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy

Minerva Pediatrica

Volumn 55, Issue 6, 2003, Pages 625-628

  Yalaz, M ^a   Aydogdu, S ^a   Ozgenc, F ^a   Akisu, M ^a   Kultursay, N ^a   Yagci, R V ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hepatolenticular degeneration; Infant, newborn; Leukopenia; Neutropenia; Penicillamine, adverse effects; Pregnancy

Indexed keywords

AMIKACIN; BERACTANT; PENICILLAMINE; SULTAMICILLIN; ZINC SULFATE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL EXAMINATION; FEMALE; HUMAN; LEUKOPENIA; MALE; NEUTROPENIA; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; RESPIRATORY DISTRESS SYNDROME; WILSON DISEASE;

CHELATING AGENTS; FEMALE; FETAL DISEASES; HEPATOLENTICULAR DEGENERATION; HUMANS; INFANT, NEWBORN; LEUKOPENIA; NEUTROPENIA; PENICILLAMINE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0842263524     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sokol RJ, Narkewicz MR. Copper and iron storage disorders. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. Philadelphia: Lippincott Williams and Wilkins; 2001.p.595-640.
2. Cuthbert JA. Wilson's disease: update of a systemic disorder with protean manifestations. Gastroenterol Clin North Am 1998;27:655-77.
3. Walshe HM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956;21:487-95.
4. Sternlieb I. Wilson's disease in asymptomatic patients. N Eng J Med 1968;278:352-4.
5. Tarnacka B, Rodo M. Procreation ability in Wilson's disease. Acta Neurol Scand 2000;101:395-8.
6. Kaushansky A, Frydman M. Endocrine studies of ovulatory disturbances in Wilson's disease (hepatolenticular degeneration). Fertil Steril 1987;47:270-3.
7. Furman B, Bashiri A. Wilson's disease in pregnancy: five successful consecutive pregnancies of the same woman. Eur J Obstet Gynecol Reprod Biol 2001;96:232-4.
8. Messner U, Gunter HH. Wilson disease and pregnancy. Review of the literature and case report. Z Geburtshilfe Neonatal 1998;202:77-9.
9. Piussan C, Mathieu M. Teratogenic risk during treatment of Wilson's disease. J Genet Hum 1985;33:357-62.
10. Gur Guven A, Gol B, Oygur N, Yegin O. Leukocyte blood picture in early neonatal period in Antalya region of Turkey. Turk J Pediatr 1994;36:123-32.
11. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979;95:89-98.
12. Kaushanksy A, Frydman M, Kaufman H, Homburg R. Endocrine studies of the ovulatory disturbances in Wilson's disease. Fertil Steril 1987;47:270-3.
13. Brewer G, Johnson RD. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology 2000;31:364-70.
14. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH Jr, editor. Major problems in internal medicine. Philadelphia: Saunders; 1984.p.121-8.
15. Endres W. D-penicillamine in pregnancy: to ban or not to ban? Klin Wochenschr 1981;59:535-7.
16. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000;89:556-61.
17. van der Klauw MM, Wilson JH. Drug-associated agranulocytosis: 20 years reporting in the Netherlands (1974-1994). Am J Hematol 1998;57:206-11.
18. Kaufman DW, Kelly JP. Drugs in the etiology of agranulocytosis and aplastic anemia. Eur J Haematol Suppl 1996;60:23-30.
19. th ed. New York: McGraw-Hill Companies; 1995.p.815-24.